Addressing the Medical Need in CLL: How BTK Inhibitors Are Improving Outcomes

Friday Satellite Symposium on Addressing the Medical Need in CLL: How BTK Inhibitors Are Improving Outcomes, preceding the 62nd ASH Annual Meeting and Exposition.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


  • Overview of the BCR Pathway and BTK in Tumor Development
  • Safety and Efficacy of BTK inhibitors in the Management of B-Cell Malignancies
  • BTK Inhibitors in Treatment-Naive CLL
  • BTK Inhibitors in Relapsed/Refractory CLL
  • BTK Inhibitors Beyond CLL


Date / Time
Event Details


Program Director
Ian Flinn, MD

Director, Lymphoma Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Susan O'Brien, MD

Associate Director for Clinical Science, Chao Family Comprehensive Cancer Center
Medical Director, Sue & Ralph Stern Center for Clinical Trials & Research
Professor, Division of Hematology/Oncology
School of Medicine
University of California, Irvine
Orange, California

John Pagel, MD, PhD

Chief of Hematologic Malignancies
Swedish Cancer Institute
Seattle, Washington

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize the use of current and emerging therapeutic strategies in the care of their patients with chronic lymphocytic leukemia.

Target Audience
This program is intended for hematologists and other clinicians involved in the management of patients with chronic lymphocytic leukemia.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate differences among agents targeting BTK in terms of molecular characteristics, selectivity, preclinical data, approved indications, dosing, safety profile, and efficacy
  • Delineate the variables to be considered in selecting treatment for CLL including tumor characteristics such as biomarkers and patient characteristics and preferences
  • Describe clinical trial results providing evidence for the important role of BTK inhibitor–based combinations in first-line treatment of CLL, including phase II and phase III trials
  • Select patients most likely to benefit from continuous first-line treatment options and those patients most likely to benefit from time-limited first-line options
  • Plan optimal, individualized therapeutic strategies for patients CLL taking into consideration recent practice-changing clinical trial results
  • Recognize and manage adverse events and toxicities associated with BTK inhibitor therapy to support adherence, appropriate dosing, quality of life, and continuation of treatment
  • Assess ongoing clinical trials evaluating currently available and emerging BTK inhibitors (and BTK inhibitor–based combinations) to aid clinical trial enrollment and predict new options in the clinic


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.